Sera from 75 patients with warts were tested for antibodies against human papillomaviruses (HPVs) in an immunoelectron microscopy test. A group of 40 patients' sera were tested against a pooled suspension of the HPVs extracted from their warts and 90% of the sera were found to be antibody-positive. Prior to serological investigation viruses from a second group of 35 patients were typed by dot blot hybridization with HPV-1 and HPV-2 DNA. According to these results the patients were divided into type 1, type 2 and non-l, non-2 virus carriers. Sera of these patients were first tested for antibodies reactive with their homologous viruses and then for antibodies against type 1 virus. More than 80% of the patients possessed antibodies against their homologous viruses, but only a small minority of sera from type 2 and non-l, non-2 virus carriers were reactive with type 1 viruses. These results suggest that the antibody reactive in the immunoaggregation test is type-specific.
Introduction
Serological tests with human papillomaviruses (HPVs) pose a major problem; HPVs do not replicate in tissue cultures so, until recently, crude tissue extracts or virus particles isolated from virus-induced lesions have been the only source of viral antigens for serological assays. In the past a variety of serological techniques (for review, see Spradbrow, 1987) were employed for demonstrating anti-HPV antibodies. These tests, which in most cases were carried out irrespective of the different virus types involved, have detected anti-HPV antibody in subjects with HPV-induced warts, although in some studies 50% or more of the subjects were free of detectable antibody (Almeida & Goffe, 1965; Genner, 1971; Pass & Maizel, 1973; Pyrh6nen & Johansson, 1975; Pfister & zur Hausen, 1978; Pyrh6nen, 1978; Kienzler et al., 1983) . It was assumed that the lack of virus-specific antibody was due to a low immunogenicity of HPV, this being at least partially determined by a low level of contact of the virus antigens with the immune system. These tests also did not reveal whether, and to what extent, the antibody response to HPV is typespecific.
Recently more sophisticated techniques have been developed for testing anti-HPV immune responses and their type specificity. The HPV-6b L1 fusion protein synthesized in genetically engineered Eseherichia eoli has been found to be reactive with sera from Condyloma 0000-9132 O 1990 SGM acuminata patients, this reaction being relatively typespecific compared to that with HPV-16 (Jenison et al., 1988) . Elsewhere, (A. Such~,nkovfi et al., unpublished) , we will report the serological reactivity of a synthetic peptide corresponding to the heptadecapeptide encoded by the C-terminal region of the HPV-6b L2 open reading frame, which is also shared by HPV-11. An ELISA test with this peptide was type-specific relative to unpublished) and also to HPV-1 (unpublished data).
Data on the type specificity of HPV antibody are still scarce and, in general, knowledge of the immunology of HPV infections is quite limited. In the present experiments we re-examined the suitability of immunoelectron microscopy (Almeida & Goffe, 1965) for demonstrating anti-HPV antibody and investigating the type specificity of the immune response. The data obtained indicate a high sensitivity of the technique in its present modification.
Methods
Patients and control subjects. A total of 75 patients were examined aged 5 to 65 years, 40 females and 35 males. The number of warts varied from one to five per patient and the duration of the disease from 2 months to 10 years. Typical myrmecia were found in 60 patients and remaining warts were classified as verrucae vulgares. The warts were removed surgically and immediately transported to the virus laboratory, where they were kept at -70 °C. At the time of surgery blood samples were taken from all the patients. Control sera were collected from six healthy infants aged 6 to 12 months and from 18 laboratory workers aged 25 to 59 years. Of the latter, four had reported a past history of warts, but not in the previous 10 years. Sera were inactivated by heat at 56 °C for 30 rain and kept at -20 °C until investigation.
Virus preparations. The removed wart samples were homogenized with sterile sand in a mortar and suspended in phosphate-buffered saline (PBS) pH 7.2. This suspension was submitted to three cycles of freezing and thawing and then clarified by centrifugation at 3000 r.p.m, for 30 rain. The pellet was resuspended in the original volume of PBS and the suspension was again clarified by centrifugation. Both supernatants were pooled and centrifuged in a Beckman SW41 rotor at 32000 r.p.m. for 150rain. The pellet was resuspended in PBS and, whenever possible, adjusted to approximately 1012 particles per ml (McCombs et al., 1966) . For the first series of experiments involving 40 patients, the individual virus samples were pooled and this mixture was used in serological tests (see below). In the subsequent tests using 36 patients, individual virus samples were kept separately. A portion of each virus suspension was typed in a dot blot hybridization test using HPV-la and HPV-2 DNA probes (see below). On the basis of these results the viruses were classified as HPV-1, HPV-2 and non-l, non-2 HPV. Each individual virus suspension was first tested with the homologous serum, then 15 type 1 viruses were pooled and used for additional serological tests. Owing to the paucity of virus particles a corresponding type 2 pool could not be prepared, nor was a pool prepared with HPV-non-1, non-2 viruses, as they may belong to several different HPV types.
Serological test. The virus-antibody reaction was monitored by electron microscopy, using a Philips Model EM 300. The reaction mixture consisted of 50 p3 of virus suspension and 1000 gl of serum diluted 1:10 (if not stated otherwise). After a 60min incubation at 37 °C the mixture was left overnight at 4 °C and then centrifuged in a Beckman SW41 rotor at 15 000 r.p.m, for 30 min at 4 °C. The sediment was resuspended in 100~tl of PBS; 50~tl of the suspension was transferred to the top of a 0-8 ~ agar layer and a carbon-coated grid was applied. After 20 rain adsorption the grid was rinsed with distilled water and the preparation was negatively stained with 2~ phosphotungstic acid adjusted to pH 6.8. The presence of antibody was demonstrated by the formation of aggregates. Fig. 1 shows an untreated virus preparation (a), a preparation treated with antibody-negative serum (b) and preparations treated with sera of low (c) and high (d) activity. It can be seen that in the presence of an antibody the particles clumped together and their outlines were obliterated by the attached antibody molecules.
Dot blot hybridization.
Recombinant DNA plasmids containing fulllength DNA sequences of HPV-la and HPV-2 were kindly provided by H. zur Hausen, Heidelberg, F.R.G. HPV DNA inserts were separated from the vector pBR322 by restriction enzyme digestion and radiolabelled by nick translation with [32p]dCTP (Rigby et al., 1977) .
Serial dilutions of DNA isolated from purified virions were spotted onto nitrocellulose filters. DNA was denatured by overlaying the filters for 10 min with Whatman 3MM filter paper soaked in 1.5 M-NaC1 and 0.5 M-NaOH. The filters were neutralized and washed by overlaying them for 10 min with Whatman 3MM filter paper soaked in 1.5 MNaCI and 1 M-Tris-HCI pH 7.2 and then twice for 5 min with Whatman 3MM filter paper soaked in 2 × SSC. The filters were airdried and the DNA was fixed by baking at 80 °C for 2 h. The filters were then prehybridized at 69 °C for 4 h in a prehybridization solution consisting of 6 × SSC, 10 x Denhardt's solution, 2 mM-EDTA pH 8.0, 0.2% SDS and 1001ag/ml of denatured calf thymus DNA. The composition of the hybridization solution was similar to that of the prehybridization solution, but contained only 1 × Denhardt's solution. Hybridization with 2 x 106 c.p.m./ml of denatured 32p-labelled HPV probe (approx. 8 x 107 c.p.m.Atg) continued at 69 °C for 16 h. The filters were then washed twice in 2 x SSC and 0-2~ SDS for 5 min at room temperature, twice in 0.5 × SSC and 0.2% SDS for 30 min at 52 °C and twice in 0.2 × SSC and 0-2% SDS under the same conditions. The filters were air-dried and exposed to X-ray film for 2 to 8 days at -70 °C, using an intensifying screen. The specificity of the hybridization was monitored by using cloned HPV-1 and HPV-2 DNAs and DNA isolated from human diploid cells.
Results
In the first series of experiments sera from 40 patients were investigated for the presence of antibodies using a pooled suspension of viruses recovered from the warts of these patients. Sera from control subjects were also tested and the results are summarized in Table 1 . Irrespective of age approximately 90% of the patients displayed antibody, the great majority of their sera being strongly reactive. Conversely none of the six healthy infants (aged 6 to 12 months) possessed antibody and only half of the 12 control adults were antibody-positive, although three of these sera were strongly reactive.
The aim of the subsequent experiments was to determine the type specificity of the reaction. Before serological tests, the individual viruses were typed in the dot blot hybridization test. Of the 35 viruses 15 were identified as type 1, 14 as type 2 and six viruses remained unidentified and were denoted non-l, non-2. The distribution of the viruses according to the patient's age is shown in Table 2 and it can be seen that most of the type 1 isolates originated mainly from children aged less than 10 years. Type 2 viruses were found in warts of older children and young adults, whereas the non-l, non-2 viruses were detected only in subjects aged over 20 years. In the antibody tests sera were first checked against their * Number reactive/number tested. t All 10 of those reactive with the homologous HPV-1 virus gave a positive reaction with the pooled HPV-I suspension.
homologous viruses, whenever a sufficient amount of virus was present. This was the case with nearly all the type 1 and non-l, non-2 virus carriers, but only a minority of type 2 virus carriers.
In the second experimental series all sera were tested with a pooled HPV-1 suspension. A similar reagent prepared with HPV-2 viruses could not be obtained because of the considerably lower virus content in the respective warts. The results are summarized in Table 3 . Approximately 80% of the sera were reactive with their homologous viruses. In this respect there was no marked difference between type 1, type 2 and non-l, non-2 virus carriers. On the other hand, the groups differed substantially in the prevalence of type 1 antibody. Eleven out of 15 HPV-1 carriers possessed demonstrable antibody, whereas only one-fifth of sera from HPV-2 patients were reactive and none of the six non-l, non-2 HPV patients was antibody-positive. These results suggest that the antibody involved in the immunoaggregation reaction is highly (possibly fully) typespecific.
It was also of interest to determine the titres of the reactive antibody. Several of the sera strongly reactive with HPV-1 at the 1:10 dilution were further tested at dilutions of 1:100, 1:400 and 1:1600. All of the seven sera tested were strongly reactive at 1:100 dilution, weakly reactive at 1 : 400 and non-reactive at the highest dilution.
No clear-cut correlation was revealed when comparing the titres and the homotypic antibody presence with the duration of the disease, number of warts and age or sex of the patients (not shown).
Discussion
The technique of immunoelectron microscopy used in this study revealed the presence of antibody to homologous viruses in more than 80% of the patients' warts. This figure is considerably higher than in previous HPVantibody studies with this technique (Almeida & Goffe, 1965; Goffe et al., 1966) , or with other techniques. Moreover, the antibody levels were quite high in a proportion of the reactants. The present data also indicate that the test is type-specific. This finding is being utilized in a study that is currently under way and which aims to identify the immunogenic surface HPV-1 structures involved in the reaction. The results of this analysis will subsequently be utilized in the search for type-specific immunogenic epitopes of the HPV types associated with human cancer.
The type of HPV present in warts was dependent on the age of the patients, with a preponderance of type 1 virus in the youngest, type 2 in the intermediate and non-1, non-2 viruses in the eldest age groups. This has to be taken into consideration when evaluating the absence of type 1 antibody in most patients with type 2-and non-l, non-2-associated warts and could imply that the respective subjects had never been infected with HPV-1. However, it is also possible that the age of the patients was involved and that antibodies previously present had dropped to subdetectable levels; Pfister & zur Hausen (1978) observed a gradual decline of HPV-1 antibody with age. Whatever the underlying mechanism is the absence of HPV-1 antibody in these subjects helped to demonstrate the type specificity of the aggregating antibody.
